 LAUSANNE, Switzerland--BUSINESS WIRE--ADC Therapeutics SA NYSE: ADCT, a commercial-stage biotechnology company leading the development of novel antibody drug conjugates ADCs to treat hematological malignancies and solid tumors, today announced the receipt of the 50 million second tranche under its convertible credit facility with Deerfield Partners, L.P. and certain of its affiliates collectively, Deerfield. Under the terms of the Facility Agreement dated April 24, 2020, Deerfield agre 